Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYSTIC first-line NSCLC trial
2015-001279-39Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + tremelimumab, Durvalumab monotherapy and Standard of care platinum-based chemotherapy (3 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Started Jul 2015; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-001279-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001279-39.